Skip to main content
SpringerLink
Log in

Parkinsonmittel

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2019

  • 2898 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Antonini A, Jost WH (2018) Intrajejunale Levodopa- und Apomorphin-Infusion zur Therapie motorischer Komplikationen bei fortgeschrittener Parkinson-Krankheit. Fortschr Neurol Psychiatr 86:55–59

    Google Scholar 

  • Birkmayer W, Hornykiewicz O (1961) Der L-Dioxyphenylalanin (L-DOPA) Effekt bei der Parkinson-Akinese. Wien Klin Wschr 78:787–788

    Google Scholar 

  • Canadian Agency for Drugs and Technologies in Health (2015) CADTH Final Recommendation: Rotigotine – Resubmission. https://www.cadth.ca/rotigotine-7

    Google Scholar 

  • Crosby NJ, Deane KH, Clarke CE (2003) Amantadine in Parkinson’s disease. Cochrane Database Syst Rev 2003; (1): CD003468

    Google Scholar 

  • Deane KH, Spieker S, Clarke CE (2004) Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 2004 Oct 18; (4): CD004554

    Google Scholar 

  • Deutsche Gesellschaft für Neurologie (2016) Leitlinien für Diagnostik und Therapie in der Neurologie: Idiopathisches Parkinson-Syndrom, Entwicklungsstufe: S3. https://www.dgn.org/leitlinien/3219-030-010-idiopathisches-parkinson-syndrom

    Google Scholar 

  • Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH, SP513 investigators (2007) Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398–2404

    Article  Google Scholar 

  • Hoy SM, Keating GM (2012) Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. Drugs 72:643–669

    Article  CAS  Google Scholar 

  • Huntington Study Group (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66:366–372

    Article  Google Scholar 

  • Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912

    Article  CAS  Google Scholar 

  • Katzenschlager R, Sampaio C, Costa J, Lees A (2003) Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev 2003; (2): CD003735

    Google Scholar 

  • Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749–759

    Article  CAS  Google Scholar 

  • Müller-Vahl KR (2007) Die Benzamide Tiaprid, Sulpirid und Amisulprid in der Therapie des Tourette-Syndroms. Eine Standortbestimmung. Nervenarzt 78:264–271

    Article  Google Scholar 

  • National Institute for Health and Care Excellence (2017) Parkinson’s disease in adults. NICE guideline. nice.org.uk/guidance/ng71

    Google Scholar 

  • Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513–520

    Article  CAS  Google Scholar 

  • Pålhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J, Nyholm D, Sydow O, Wainwright M, Widner H, Johansson A (2012) Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126:e29–33

    Article  Google Scholar 

  • Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, for The 056 Study Group (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484–1491

    Article  CAS  Google Scholar 

  • Rascol O, Lozano A, Stern M, Poewe W (2011) Milestones in Parkinson’s disease therapeutics. Mov Disord 26:1072–1082

    Article  Google Scholar 

  • Schapira AH (2004) Restless legs syndrome: an update on treatment options. Drugs 64:149–158

    Article  CAS  Google Scholar 

  • Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M (2011) Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev 2011 Mar 16; (3): CD006009

    Google Scholar 

  • Silver DE, Ruggieri S (1998) Initiating therapy for Parkinson’s disease. Neurology 50(Suppl 6):S18–S22 (discussion S44–S48)

    Article  CAS  Google Scholar 

  • Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18–27

    Article  CAS  Google Scholar 

  • The Parkinson Study Group (2004a) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508

    Article  Google Scholar 

  • The Parkinson Study Group (2004b) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044–1053

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Heidelberg, Deutschland

    Prof. em. Dr. med. Ulrich Schwabe

  2. Medizinische Hochschule Hannover, Institut für Pharmakologie, Hannover, Deutschland

    Prof. Dr. med. Roland Seifert

Authors
  1. Prof. em. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Roland Seifert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Schwabe .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Köln, Nordrhein-Westfalen, Germany

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK, Berlin, Berlin, Germany

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Schwabe, U., Seifert, R. (2019). Parkinsonmittel. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2019. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59046-1_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59046-1_40

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59045-4

  • Online ISBN: 978-3-662-59046-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation